Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.65 |
| ▸ | FEN1 | P39748 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686217 | 0.84 | ERCC5 (0.59) | ERCC5FEN1KCNH2GSK3BL3MBTL1 | |
| SCHEMBL3864104 | 0.83 | NPC1 (0.58) | GSK3BL3MBTL1MAPTLMNAKDM4E | |
| SCHEMBL9349345 | 0.83 | ERCC5 (0.57) | ERCC5FEN1KCNH2GSK3BL3MBTL1 | |
| SCHEMBL6341613 | 0.81 | PLOD2 (0.53) | MAPTKDM4ERAB9ANPC1HPGD | |
| SCHEMBL3365857 | 0.81 | KMT2A (0.60) | KCNH2GSK3BMAPTLMNAPOLB | |
| SCHEMBL6511539 | 0.81 | HAO1 (0.59) | GSK3BL3MBTL1MAPTLMNARAB9A | |
| SCHEMBL1109662 | 0.81 | ERCC5 (0.64) | ERCC5FEN1GSK3BMAPTLMNA | |
| SCHEMBL1531237 | 0.81 | ERCC5 (0.58) | ERCC5FEN1KCNH2GSK3BL3MBTL1 | |
| SCHEMBL25268811 | 0.81 | HPGD (0.53) | KDM4EPOLBHPGDALDH1A1 | |
| SCHEMBL30481570 | 0.81 | HPGD (0.53) | KDM4EPOLBHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3589630-B1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2020-05-21 | — | — | US | disclosed |
| CN-110621672-A | Cyclic sulfonamide compounds and methods of use thereof | 组装生物科学股份有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018160878-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-1996038442-A1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5563165-A | PROSTAGLANDIN INHIBITOR; FDA ORANGE BOOK LISTED PATENT FOR CELEBREX | G. D. SEARL & CO. (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5510496-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5504215-A | Substituted pyrazolyl benzenesulfonamide compounds for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-04-02 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | ERCC5 1844/4885FEN1 3332/4885KCNH2 4830/4885 |
| US-11078170-B2 | Cyclic sulfamide compounds and methods of using same | HCCS, HAVCR2, SLC10A1 | ERCC5 1844/4885FEN1 3332/4885KCNH2 4830/4885 |
| US-20200157070-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | ERCC5 1844/4885FEN1 3332/4885KCNH2 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.